🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

More details will be interesting: whether concur/adjuv Nivo non-inferior to or worse than adjuv Durva? Not same negative as Pacific 2 (Durva vs placebo). Pierre Blanchard, MD Benjamin Besse Bristol Myers Squibb Provides Update on Phase 3 CheckMate -73L Trial news.bms.com/news/corporate…

Bispecific PD-1/VEGF antibody Ivonescimab (AK112) showed better PFS than pembrolizumab in 1L NSCLC TPS>=1, first head-to-head trial vs anti-PD-1 ICI, waiting for OS result. Trial with AK112 in HNSCC expected. d.planchard Pierre Blanchard, MD

Totally agree, OS similar, it is possible to use the osimertinib later without OS loss.

Another disappointing result of combination IO and RT, even with SBRT... While huge benefit in phase 2 trial. Similar situation as Trilynx with IAPi in LA-HNSCC. Pierre Blanchard, MD Benjamin Besse

Big PFS gain with HR 0.51 in favor of Ivonescimab (AK112) vs Pembro 1L NSCLC compared with HR 0.78 in LEAP-007 Pembrolizumab +/- Lenvatinib, could we expect OS gain? Hope AK112 also in HNSCC Pierre Blanchard, MD

Innovative GORTEC trial at #ESMO2024: prophylactic neck #radiotherapy replaced by IO durvalumab. Low rate of neck relapse BUT frail population with high toxicity and lots of early death (may have underestimated the true risk of nodal relapse). Congrats Joel Castelli & team

Congrats to my friend Yungan TAO & GORTEC for this huge trial of IO in LA HNSCC Avelumab-cetuximab inferior to cisplatin CRT in fit patients but superior to cetuximab-RT for PFS in cisplatin ineligible population. #ESMO2024

ESMO - Eur. Oncology 🔹 Dr Tao présente les resultats de l'étude REACH à ESMO - Eur. Oncology.

OS result of keynote A18 confirmed the benefit of pembrolizumab when combining with concurrent chemo- radiotherapy, in contrast to our negative results of IO + RT in HNSCC Pierre Blanchard, MD Melvin LK CHUA | FRCR, PhD, FASCO

Wrapped another great interview with Yungan TAO of Gustave Roussy who walked us through data from the final analysis of the phase 3 GORTEC 2017-01 REACH trial of avelumab plus cetuximab/RT vs SOCs in patients with LA-SCCHN. More from ESMO - Eur. Oncology #ESMO24 here: onclive.com/conference/esm…

Thank you Melvin LK CHUA | FRCR, PhD, FASCO , surely synergy Avelumab+cetuximab on distant control, and a little + tox during RT. Difficult to say no synergy anti-PD-1 (PD-L1) + cDDP, waiting for long-term outcome KeyNote-412 next ASCO. Still KeyNote-689 and GORTEC 2018-01 Nivo-postOP very soon

Toripalimab, anti-PD-1 of TopAlliance finally approved by EMA for 1L R/M nasophayrgeal cancer and also 1L esophageal SCC. Pierre Blanchard, MD Melvin LK CHUA | FRCR, PhD, FASCO

KN689 positive, Neoadjuvant pembrolizumab 2 cycles before surgery improved EFS compared to surgery in LA-HNSCC! Pierre Blanchard, MD Melvin LK CHUA | FRCR, PhD, FASCO

KN689 is the 1st +ve trial IO (+surgery -RT) in LA-HNSCC, neoadjuvant role PD-1 probably essential, but we should not ignore CONCOMITANT use of pembro during post-OP (C)RT. Waiting for GORTEC Nivo-postOP results to clarify definitely neoadjuvant role.

Why are Western pharmaCos licensing so many Chinese drugs lately? Is China going to do all our drug discovery in the future? My thoughts in a new post. This post has languished in drafts for a while, but the Merck+Hansoh deal motivated me to finish it up atelfo.github.io/2024/12/20/wil…

Honored to contribute as co-PI to our Phase 3 trial NIVOPOSTOP GORTEC 2018-01 evaluating nivolumab in addition to post-operative concurrent CRT for resected HR LAHNSCC pts, which met its primary endpoint of DFS across all comers. Pierre Blanchard, MD Gustave Roussy

GORTEC announces that the NIVOPOSTOP study (NCT03576417) met its primary endpoint of Disease-Free survival (DFS) across all comers high risk resected HNSCC. Combined with KN689 this represents the 2nd positive IO trial in the postop setting. prnewswire.com/news-releases/…

Hot of the press IJROBP - The Red Journal: Role of SABR in oligometastatic head and neck cancer: a GORTEC randomized trial Full text here: doi.org/10.1016/j.ijro…

Pembrolizumab (before surgery and during post-operative radiotherapy + after RT) approved in CPS>=1 resectable LA-HNSCC fda.gov/drugs/resource…

🧪#ASCO2025 In-Depth! Dr Yungan TAO on KEYNOTE-412: ✔️ Pembro + CRT: 5y EFS 55% vs 47% ✔️CPS ≥20 = best results 🎥 Watch now bit.ly/4mLvOXR #MediMix #HNSCC #PDL1 #ImmunoCRT